Legal group urges CMS to cover BiDil for black Medicare patients
Group contends CMS is promoting a less expensive generic substitute.
The Centers for Medicare and Medicaid Services' decision not to provide insurance coverage for Bidil (isosorbide dinitrate/hydralazine, Nitromed) when it is the only drug approved to treat African Americans with heart failure is racially insensitive. So contends the Washington Legal Foundation (WLF), a public interest law and policy center. So WLF has petitioned CMS to revise its reimbursement policies for the cardiovascular drug. WLF said CMS is promoting a less expensive generic substitute, even though the Food and Drug Administration has determined that there is no interchangeable product for BiDil.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, clickhere.
How PBMs Impede Pharmacists’ Ability to Perform Clinical Services | APhA 2025
March 31st 2025Antonio Ciaccia, President of 3 Axis Advisors, led a discussion on pharmacy benefit manager reform and how the inability to pass legislation has led to increased financial hardships in community pharmacy.
